[{"address1": "201 Brookline Avenue", "address2": "Suite 901", "city": "Boston", "state": "MA", "zip": "02215", "country": "United States", "phone": "857 320 4900", "website": "https://www.tangotx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 140, "companyOfficers": [{"maxAge": 1, "name": "Dr. Barbara L. Weber M.D.", "age": 66, "title": "President, CEO & Director", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 1039811, "exercisedValue": 0, "unexercisedValue": 9991192}, {"maxAge": 1, "name": "Dr. Adam S. Crystal M.D., Ph.D.", "age": 46, "title": "President of Research & Development", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 977216, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alan  Ashworth FRS, Ph.D.", "age": 62, "title": "Founder & Member of Scientific Advisory Board", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Levi  Garraway M.D., Ph.D.", "age": 54, "title": "Founder", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William G. Kaelin Jr., M.D.", "age": 65, "title": "Founder & Member of Scientific Advisory Board", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Timothy K. Lu M.D., Ph.D.", "age": 42, "title": "Founder", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Antoni  Ribas M.D., Ph.D.", "age": 56, "title": "Founder & Member of Scientific Advisory Board", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy  Redfern", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles  Davis Ph.D.", "title": "Senior Vice President of Clinical Pharmacology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Heather  DiBenedetto M.S.", "title": "Chief Development Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 4, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.91, "open": 7.15, "dayLow": 6.89, "dayHigh": 7.31, "regularMarketPreviousClose": 6.91, "regularMarketOpen": 7.15, "regularMarketDayLow": 6.89, "regularMarketDayHigh": 7.31, "beta": 0.819, "forwardPE": -4.890411, "volume": 452199, "regularMarketVolume": 452199, "averageVolume": 901646, "averageVolume10days": 781820, "averageDailyVolume10Day": 781820, "bid": 7.18, "ask": 7.2, "bidSize": 100, "askSize": 100, "marketCap": 765008128, "fiftyTwoWeekLow": 6.33, "fiftyTwoWeekHigh": 13.005, "priceToSalesTrailing12Months": 17.99638, "fiftyDayAverage": 9.0174, "twoHundredDayAverage": 9.18645, "currency": "USD", "enterpriseValue": 480737472, "profitMargins": -2.74038, "floatShares": 49373241, "sharesOutstanding": 107144000, "sharesShort": 10813285, "sharesShortPriorMonth": 10214899, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.1009, "heldPercentInsiders": 0.12926, "heldPercentInstitutions": 0.90408, "shortRatio": 8.27, "shortPercentOfFloat": 0.1863, "bookValue": 2.314, "priceToBook": 3.0855663, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -116491000, "trailingEps": -1.15, "forwardEps": -1.46, "enterpriseToRevenue": 11.309, "enterpriseToEbitda": -3.699, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "TNGX", "underlyingSymbol": "TNGX", "shortName": "Tango Therapeutics, Inc.", "longName": "Tango Therapeutics, Inc.", "firstTradeDateEpochUtc": 1599139800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "90cada1d-9f83-3886-ad2a-ac647db270d6", "gmtOffSetMilliseconds": -14400000, "currentPrice": 7.14, "targetHighPrice": 19.0, "targetLowPrice": 13.0, "targetMeanPrice": 16.13, "targetMedianPrice": 17.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 322111008, "totalCashPerShare": 3.006, "ebitda": -129959000, "totalDebt": 37837000, "quickRatio": 7.343, "currentRatio": 7.486, "totalRevenue": 42509000, "debtToEquity": 15.277, "revenuePerShare": 0.406, "returnOnAssets": -0.21761999, "returnOnEquity": -0.5058, "freeCashflow": -63782752, "operatingCashflow": -120066000, "revenueGrowth": 0.361, "grossMargins": -2.18067, "operatingMargins": -1.48689, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-17"}]